LCI699
LCI699 is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
1
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
Safety and Efficacy of LCI699 in Cushing's Disease Patients
Clinical Trials (6)
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
Safety and Efficacy of LCI699 in Cushing's Disease Patients
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6